GlassScriptPhysician profile
Senka Hadzic
NPI 1205101003
$6,164.49
in general payments reported to CMS, 2019-2025
29 companies · $1,578 in 2025
The $1,578 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $255 · 2022: $356 · 2023: $1,620 · 2024: $2,355 · 2025: $1,578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,553.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $993.24 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $650.44 | 2023-2025 | Jardiance |
| Pfizer INC. | $606.49 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $602.86 | 2022-2025 | Farxiga, Lokelma, Wainua |
| Merck Sharp & Dohme LLC | $493.51 | 2023-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $464.08 | 2021-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $452.22 | 2021-2025 | Lifevest |
| Amgen INC. | $293.25 | 2023-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $222.80 | 2023-2024 | Xarelto, Opsumit |
| Bayer Healthcare Pharmaceuticals INC. | $213.97 | 2022-2025 | |
| Lilly USA, LLC | $195.09 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Edwards Lifesciences Corporation | $176.20 | 2024-2025 | Pascal, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Lexicon Pharmaceuticals, INC. | $149.27 | 2023-2024 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $113.20 | 2024 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $80.76 | 2023-2024 | Onpattro |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $68.88 | 2023-2024 | Assure Wcd |
| Novo Nordisk INC | $58.60 | 2025 | Wegovy |
| Kiniksa Pharmaceuticals, LTD. | $50.62 | 2023 | Arcalyst |
| Bridgebio Pharma, INC. | $45.85 | 2025 | Attruby |
| Actelion Pharmaceuticals US, INC. | $30.66 | 2024 | Uptravi, Opsumit |
| Boston Scientific Corporation | $28.48 | 2025 | Watchman Flx |
| Altathera Pharmaceuticals LLC | $28.03 | 2025 | Sotalol Hydrochloride |
| Innovation Technologies INC | $27.84 | 2023 | Irrisept |
| Corcept Therapeutics | $25.89 | 2025 | Korlym |
| Cardiva Medical, INC. | $24.64 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Chiesi USA, INC. | $22.22 | 2024 | Kengreal, Cleviprex |
| Atricure, INC. | $18.05 | 2024 | |
| Lantheus Medical Imaging, INC. | $14.28 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $13.07 | 2023 | Livalo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Senka Hadzic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.